Other Urinary, Phase I

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Volunteers
Health Professionals

What is the purpose of this trial?

This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Chioma Amenechi

chioma.amenechi@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Michael Hurwitz, MD, PhD
Associate Professor of Internal Medicine (Medical Oncology)

Sub-Investigators

Last Updated
01/17/2024
Study HIC
#2000034639